NVCN.TO - Neovasc Inc.

Toronto - Toronto Delayed Price. Currency in CAD
2.88
-0.01 (-0.35%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close2.89
Open2.92
Bid2.82 x 0
Ask2.93 x 0
Day's Range2.83 - 2.96
52 Week Range2.83 - 212.00
Volume95,269
Avg. Volume88,384
Market Cap56.043M
Beta (3Y Monthly)5.59
PE Ratio (TTM)N/A
EPS (TTM)-16.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.43
  • CNW Group4 days ago

    Neovasc Announces Publication of a Peer-Reviewed Article on Tiara™ Cases in Circulation: Cardiovascular Interventions

    VANCOUVER, Oct. 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an original article was published in Circulation: Cardiovascular Interventions titled 'Transcatheter Mitral Valve Replacement in Patients With Previous Aortic Valve Replacement', which reports for the first time ever the experience of transcatheter mitral valve replacement ("TMVR") using Neovasc's Tiara™ ("Tiara") valve in patients with previous aortic valve replacement. The Tiara is a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation ("MR"), one of the most prevalent valvular heart diseases in western countries.  Tiara is not currently approved for commercial sale in any geographies.

  • Baystreet10 days ago

    Stocks in play: Neovasc Inc.

    Announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation to ...

  • CNW Group10 days ago

    Neovasc Reducer™ Granted Breakthrough Device Designation from FDA

    VANCOUVER, Oct. 10, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the U.S. Food and Drug Administration (the "FDA") has granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer"), a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S. The FDA grants Breakthrough Device designation in order to expedite the development and review of a device that demonstrates compelling potential to provide a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases.

  • CNW Group11 days ago

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Oct. 9, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification from the Nasdaq Hearings Panel (the "Panel") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the "Nasdaq"), that it is in compliance with all other applicable continued listing requirements and that the Panel has determined to continue the listing of the Company's common shares on the Nasdaq. Words and phrases such as "continue", "may", "will" and "growing", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group17 days ago

    Neovasc Announces Positive 12-week Follow-up Data from the First U.S. Patient Implanted with a Neovasc Reducer™

    VANCOUVER, Oct. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News)(TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced positive 12-week follow-up data from the first U.S. patient implanted with a Neovasc Reducer™ (the "Reducer"), a CE-Marked medical device for the treatment of refractory angina. The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.

  • ACCESSWIRE19 days ago

    Today's Research Reports on GeneNews, Titan Medical, Neovasc and Trillium Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 1, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
    Zacks23 days ago

    Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

    Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • CNW Grouplast month

    Neovasc's Tiara and Reducer to be Featured at TCT 2018 Conference

    VANCOUVER, Sept. 20, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News)(TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device used for the treatment of refractory angina, will both be featured in several presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium to take place September 21-25, 2018 in San Diego, California.

  • CNW Grouplast month

    Neovasc Announces 100th Patient to Receive Reducer Therapy in Germany

    VANCOUVER, Sept. 19, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that a Neovasc Reducer™ (the "Reducer") has now been implanted in 100 patients in Germany. The Reducer is a wire mesh implanted into a vein in the heart which treats patients with refractory angina. A growing number of patients suffer from significant angina despite optimal medication and prior revascularisations (via percutaneous coronary intervention or coronary artery bypass graft), or when revascularization is not feasible or when the risks is too great.

  • CNW Grouplast month

    Neovasc Announces Amendments to Outstanding Convertible Notes, including 1-Year Extension of Note Maturity Date

    VANCOUVER, Sept. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News)(TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020. Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen, Neovasc's President and Chief Executive Officer.

  • CNW Grouplast month

    Neovasc Announces Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule

    VANCOUVER, Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News)(TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today (1) that it has received the decision of the Nasdaq Hearings Panel (the "Panel") to grant it a extension until October 15, 2018 to regain compliance with the US$1.00 minimum bid price requirement and (2) the Company's plans to execute the reverse stock split (share consolidation), approved at its Annual General and Special Meeting of Shareholders on June 4, 2018. The Nasdaq Stock Market LLC ("Nasdaq") held an oral hearing on August 30, 2018, at which the Panel considered Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Company's common shares (the "Common Shares") from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement.

  • CNW Grouplast month

    Neovasc Provides Initial Comments on Lawsuit

    VANCOUVER, Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News)(TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, has been made aware of a lawsuit filed by Endovalve Inc. and Micro Interventional Devices, Inc. (the "Plaintiffs") in the U.S. District Court for the District of New Jersey including certain allegations relating to Neovasc's transcatheter mitral valve technology, including the Tiara™ ("Tiara") device. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's plans and expectations concerning the lawsuit filed against the Company, the Company's intention to defend itself vigorously, and the growing cardiovascular marketplace.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Neovasc, Trillium Therapeutics, Cipher Pharmaceuticals and GeneNews

    NEW YORK, NY / ACCESSWIRE / August 29, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group2 months ago

    Neovasc Announces Second Quarter 2018 Financial Results

    NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference ...

  • What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?
    Simply Wall St.2 months ago

    What Does Neovasc Inc’s (TSE:NVCN) Ownership Structure Look Like?

    In this article, I’m going to take a look at Neovasc Inc’s (TSE:NVCN) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.Read More...

  • CNW Group2 months ago

    Neovasc Announces Updated Presentation Time at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 8, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group2 months ago

    Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

    VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116. In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical centers in Milan, Tel Aviv and Antwerp. The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory angina.

  • CNW Group2 months ago

    Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 6, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group3 months ago

    Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

    VANCOUVER, Aug. 3, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVCN.TO - News), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research Group at the University of Pennsylvania (together, "Penn"). This Agreement resolves certain potential claims against the Company that were described in the Company's Annual Report on Form 20-F and management's discussion and analysis for Q1. This agreement does not impact either Penn or Neovasc's patent rights. Tiara™ ("Tiara") is Neovasc's minimally invasive transcatheter device for patients who experience severe mitral regurgitation ("MR").

  • CNW Group3 months ago

    Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

    NASDAQ, TSX: NVCN VANCOUVER , Aug. 2, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Cipher Pharmaceuticals, Aurinia Pharmaceuticals, GeneNews and Neovasc

    NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • CNW Group3 months ago

    Nasdaq Schedules Hearing to Consider Neovasc's Appeal of Delisting Determination

    VANCOUVER, July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that The Nasdaq Stock Market LLC ("Nasdaq") has scheduled an oral hearing for August 30, 2018, at which the Nasdaq Hearings Panel (the "Panel") will consider Neovasc's appeal of the Nasdaq Listing Qualifications Staff (the "Staff") decision to delist the Neovasc's securities from the Nasdaq Capital Market for non-compliance with the US$1.00 minimum bid price requirement. Words and phrases such as "believes", "can", "scheduled" and "will", and similar words or expressions, are intended to identify these forward-looking statements.

  • CNW Group3 months ago

    Neovasc Announces Filing of "Administrative" Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

    NASDAQ, TSX: NVCN VANCOUVER , July 16, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base ...

  • CNW Group3 months ago

    Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

    NASDAQ, TSX: NVCN VANCOUVER , July 9, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter ...

  • CNW Group4 months ago

    Tiara and Reducer Featured at CSI Frankfurt 2018

    VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ ("Reducer"), a CE-Marked medical devices used for the treatment of refractory angina, were both featured in presentations at the CSI Frankfurt 2018 conference held on June 27-30, 2018 in Frankfurt, Germany. This year, new Reducer clinical data was presented in a scientific session entitled: Structural meets coronary – Reducer for the treatment of refractory angina. The clinical data presented again demonstrated the clinical benefits of the Reducer in improving quality of life of patients suffering from disabling angina, as well as improving exercise capability.